Albireo Granted Orphan Designation by European Commission For Lead Product Candidate A4250 for Treatment of Biliary Atresia
Albireo Granted Orphan Designation by European Commission For Lead Product Candidate A4250 for Treatment of Biliary Atresia
PDF Version
Expands lead product candidate?s development potential in rare cholestatic liver diseases
Provides 10 years market exclusivity upon approval plus 2 years upon completion of PIP